Pharma companies continue to evaluate novel ways to increase their return on investment and generate shareholder value, basic earnings per share (EPS), plus sto 19 September 2022
Last month, Belgo-Dutch autoimmune diseases specialist argenx announced the European Commission (EC) approval of Vyvgart (efgartigimod alfa-fcab) as an add-on t 19 September 2022
Sophisticated products in the form of biologics and large molecules, produced by living materials from humans, animals, plants, or microorganisms, are increasin 13 September 2022
With the final presentations of this year’s meeting of the European Society of Medical Oncology (ESMO 22) in full swing, there is a lot for the scientific commu 12 September 2022
Yaneth Giha, the first woman to serve as executive director of FIFARMA, the Latin American Federation of the Pharmaceutical Industry, spoke to Angel Galindo, Th 1 September 2022
The annual meeting of the European Society of Medical Oncology (ESMO) kicks off in Paris on 9 September.and early indications are the event could be full of pra 29 August 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news